By Counterforce Health Team in Alecensa (alectinib) —

If Alecensa (Alectinib) Isn't Approved by Cigna in New York: Formulary Alternatives & Exception Paths

Answer Box: When Cigna Denies Alecensa (Alectinib) in New York

If Cigna denies Alecensa (alectinib) for ALK-positive NSCLC, you have three main paths: try formulary alternatives (crizotinib, brigatinib), request a formulary exception with clinical evidence, or appeal through New York's external review process. Most denials stem from missing ALK test results or step therapy requirements. Your first step: contact your oncologist to verify your ALK mutation status documentation and review Cigna's preferred alternatives. New York's Department of Financial Services provides binding external appeals within 30 days if internal appeals fail.

Table of Contents

  1. When Alternatives Make Sense
  2. Typical Formulary Alternatives
  3. Pros and Cons Overview
  4. Exception Strategy for Alecensa
  5. Switching Logistics
  6. Re-trying for Alecensa Later
  7. Appeals Playbook for New York
  8. FAQ

When Alternatives Make Sense

Before pursuing a lengthy exception process, consider whether Cigna's formulary alternatives might work for your situation. This approach makes the most sense when:

  • You're treatment-naive (haven't tried any ALK inhibitors yet)
  • Step therapy is required and you need coverage quickly
  • Alecensa isn't available due to supply issues or formulary restrictions
  • Your oncologist agrees an alternative could be equally effective
Note: Never switch medications without your oncologist's guidance. ALK inhibitors have different resistance patterns and side effect profiles.

Availability and Coverage Criteria

Cigna typically covers ALK inhibitors under their specialty pharmacy benefit through Express Scripts/Accredo. Prior authorization is required for most ALK inhibitors, but some may have fewer restrictions than Alecensa.

Key requirements across all ALK inhibitors:

  • Age ≥18 years
  • Confirmed ALK-positive NSCLC via FDA-approved testing
  • Advanced, metastatic, or recurrent disease
  • ECOG performance status 0-2

Typical Formulary Alternatives

Based on current ALK inhibitor market data, here are the main alternatives Cigna may prefer over Alecensa:

First-Generation ALK Inhibitors

Crizotinib (Xalkori)

  • Often preferred as first-line by insurers due to cost
  • FDA-approved for ALK-positive metastatic NSCLC
  • May require step-through before second-generation options

Second-Generation Alternatives

Brigatinib (Alunbrig)

  • Direct competitor to Alecensa
  • Approved for first-line and post-crizotinib treatment
  • May have similar formulary restrictions

Ceritinib (Zykadia)

  • Alternative second-generation option
  • Active against some resistance mutations
  • Different dosing schedule (450mg daily with food)

Third-Generation Options

Lorlatinib (Lorbrena)

  • Reserved for progression on prior ALK inhibitors
  • Best CNS penetration but highest toxicity profile
  • Cigna covers for 1 year if criteria met

Pros and Cons Overview

Drug Key Advantages Access Considerations Monitoring Requirements
Crizotinib Often first-line covered; established safety Shorter progression-free survival; more toxicity LFTs, ECGs, vision tests
Brigatinib Balanced efficacy/toxicity; CNS activity Similar PA requirements to Alecensa LFTs, CPK, blood pressure
Ceritinib Active against resistance mutations GI tolerability issues LFTs, lipase, glucose
Lorlatinib Superior CNS penetration Reserved for later lines; neurologic AEs Lipids, cognitive assessment

Testing Requirements

All alternatives require the same ALK-positive confirmation as Alecensa. Acceptable tests include:

  • FISH (fluorescence in situ hybridization)
  • IHC (immunohistochemistry)
  • NGS (next-generation sequencing)
Tip: If your ALK test was done outside New York, ensure the lab report clearly states "ALK-positive" or "ALK rearrangement detected" to avoid delays.

Exception Strategy for Alecensa

When formulary alternatives aren't suitable, request a formulary exception through Cigna's medical necessity process.

Strongest Exception Arguments

Clinical Superiority Evidence:

  • Cite the ALEX trial showing Alecensa's longer progression-free survival (25.7 vs 10.4 months vs crizotinib)
  • Reference superior CNS activity if you have brain metastases
  • Document better tolerability profile (41% vs 50% grade 3-5 adverse events)

Contraindications to Alternatives:

  • Prior intolerance to crizotinib or brigatinib
  • Drug interactions with alternatives
  • Specific comorbidities favoring Alecensa

Required Documentation

Your oncologist should submit:

  1. Medical necessity letter citing NCCN guidelines and clinical evidence
  2. ALK test results with clear positive confirmation
  3. Prior therapy records if applicable (failures, intolerances)
  4. Staging information (imaging, pathology reports)
  5. Treatment plan including dosing and monitoring schedule
From our advocates: We've seen formulary exceptions succeed when oncologists include specific citations from the FDA label and peer-reviewed studies, rather than generic medical necessity language. The key is demonstrating why Alecensa is uniquely appropriate for this patient's clinical situation.

Switching Logistics

If you need to try an alternative first, coordinate the transition carefully with your healthcare team.

Provider Coordination Steps

  1. Discuss sequencing strategy with your oncologist
  2. Plan monitoring schedule for the new medication
  3. Document baseline status before switching
  4. Set reassessment timeline (typically 8-12 weeks)
  5. Prepare for potential switch back to Alecensa

Pharmacy Coordination

Most ALK inhibitors require specialty pharmacy dispensing through Accredo. Your oncologist will need to:

  • Submit new prior authorization for the alternative
  • Coordinate delivery timing to avoid treatment gaps
  • Provide patient education materials

Re-trying for Alecensa Later

If an alternative doesn't work, you'll have stronger grounds for Alecensa approval.

What to Document During Alternative Therapy

Efficacy Markers:

  • Imaging results (progression, stable disease, response)
  • Tumor marker trends (if applicable)
  • Performance status changes

Tolerability Issues:

  • Specific adverse events with grades
  • Dose reductions or treatment delays
  • Quality of life impacts

Clinical Rationale for Switch:

  • Disease progression with imaging evidence
  • Intolerable side effects despite management
  • New clinical factors (CNS metastases, drug interactions)

Timing Your Re-request

Most insurers require at least 8-12 weeks of alternative therapy before considering a switch, unless there are safety concerns. Document everything during this period to build your case.

Appeals Playbook for New York

New York provides robust appeal rights through the Department of Financial Services (DFS).

Internal Appeals Process

Timeline: 180 days from denial to file; 30 days for Cigna decision Submission: Via Cigna member portal or provider portal Required: Denial letter, medical records, prescriber letter

External Review Process

If Cigna denies your internal appeal, New York's external review program provides binding independent review.

Key Details:

  • Filing deadline: 60 days from internal denial (4 months from original denial)
  • Review timeline: 30 days standard, 72 hours expedited
  • Cost: No fee for consumers
  • Decision: Binding on Cigna

Required Documentation:

  • Internal appeal denial letter
  • Complete medical records
  • Prescriber attestation
  • Peer-reviewed studies supporting medical necessity
Note: New York's external reviewers frequently overturn oncology denials when NCCN guidelines support the treatment and clinical evidence is complete.

When to Request Expedited Review

Request expedited processing (72-hour decision) if:

  • Your health would be seriously jeopardized by delay
  • You're experiencing disease progression
  • Standard timeline would significantly reduce treatment effectiveness

Counterforce Health Support

Counterforce Health helps patients and clinicians navigate complex prior authorization and appeals processes. Their platform analyzes denial letters, identifies specific coverage criteria, and generates evidence-backed appeals tailored to each payer's requirements. For ALK inhibitor denials, they can help identify the strongest clinical arguments and compile the necessary documentation to support your case.

Frequently Asked Questions

How long does Cigna prior authorization take in New York? Standard review is 72 hours for non-urgent requests, 24 hours for urgent/expedited requests. Express Scripts handles most specialty drug reviews.

What if Alecensa is completely non-formulary? Request a formulary exception with clinical documentation. New York law requires insurers to have an exception process for medically necessary non-formulary drugs.

Can I get expedited appeals for cancer treatment? Yes, New York allows expedited external appeals for urgent medical needs, with decisions within 72 hours for serious health risks.

Do I need to try crizotinib first? This depends on your specific Cigna plan's step therapy requirements. Some plans require first-generation ALK inhibitor trial before approving newer agents.

What counts as "medical necessity" for ALK inhibitors? Generally: ALK-positive confirmation, appropriate staging, failure of/contraindication to preferred alternatives, and alignment with clinical guidelines.

How successful are appeals in New York? External appeals overturn roughly 50-60% of denials statewide, with oncology appeals having higher success rates when supported by clinical guidelines.

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Always consult with your healthcare provider and insurance plan for specific coverage decisions. For personalized assistance with insurance appeals in New York, contact the Community Health Advocates helpline at 888-614-5400.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.